Annoviant
Annoviant is a healthcare innovation company dedicated to developing medical devices that transform and save lives worldwide. The company is focused on exploring cardiovascular applications of breakthrough technology that improves soft tissue healing, with a particular emphasis on pediatric and adult heart disease treatments. Annoviant's mission is to create innovative solutions that address clinical challenges such as calcification, thrombosis, and infection, and to reduce healthcare costs by eliminating the need for multiple surgeries. Their flagship technology, TxGuard™, is a patented, regenerative tissue platform that heals and grows with the patient, aiming to improve quality of life and clinical outcomes.
Industries
Nr. of Employees
small (1-50)
Annoviant
2972 Webb Bridge Road, Alpharetta, GA 30009
Patents
Products
Pulmonary valved conduit (regenerative decellularized scaffold)
A decellularized, stabilized pulmonary valved graft engineered to resist calcification and thrombosis while enabling host-cell infiltration and remodeling; developed for pediatric congenital heart disease applications.
Materials for transcatheter valve leaflets
Stabilized decellularized tissue materials intended for use as valve leaflet materials in transcatheter valve replacement systems with reduced calcification and retained pliability.
Vascular patch for large-artery reconstruction
Decellularized, stabilized pericardial or intestinal submucosa-based patch intended for arterial reconstruction, suture-line reinforcement, and repair of intracardiac or vascular defects.
Small-diameter vascular grafts (SDVG)
Fabrication and processing of decellularized, stabilized small-caliber vascular grafts intended as off-the-shelf alternatives to autologous grafts for coronary artery bypass and small vessel reconstruction.
Pulmonary valved conduit (regenerative decellularized scaffold)
A decellularized, stabilized pulmonary valved graft engineered to resist calcification and thrombosis while enabling host-cell infiltration and remodeling; developed for pediatric congenital heart disease applications.
Materials for transcatheter valve leaflets
Stabilized decellularized tissue materials intended for use as valve leaflet materials in transcatheter valve replacement systems with reduced calcification and retained pliability.
Vascular patch for large-artery reconstruction
Decellularized, stabilized pericardial or intestinal submucosa-based patch intended for arterial reconstruction, suture-line reinforcement, and repair of intracardiac or vascular defects.
Small-diameter vascular grafts (SDVG)
Fabrication and processing of decellularized, stabilized small-caliber vascular grafts intended as off-the-shelf alternatives to autologous grafts for coronary artery bypass and small vessel reconstruction.
Expertise Areas
- Regenerative biomaterials
- Cardiovascular device development
- Preclinical testing and large-animal models
- GMP manufacturing scale-up for biologics
Key Technologies
- Decellularization of biological tissues
- Antioxidant/polyphenol-based scaffold stabilization
- Enzyme-resistant collagen/elastin matrix treatments
- Sterilization and shelf-stable packaging for biologic scaffolds
News & Updates
Funding from NIH supports development of a regenerative conduit for pediatric congenital heart disease, resistant to calcification, thrombosis, and infection.
Annoviant’s innovative technology aims to improve outcomes in cardiac surgeries by providing tissue that grows with the patient.
A profile of Annoviant’s mission to develop regenerative tissue solutions for heart disease, emphasizing their TxGuard platform and clinical progress.
Details about NIH funding to support the development of a regenerative conduit for pediatric heart patients.
Received a $2.99 million SBIR Phase 2b grant from NIH to develop and commercialize a regenerative conduit for pediatric heart disease.
Awarded a $1.85 million NIH SBIR Phase II grant to further develop a tissue-engineered pulmonary valve conduit for children with congenital heart disease.
Funding from NIH supports development of a regenerative conduit for pediatric congenital heart disease, resistant to calcification, thrombosis, and infection.
Annoviant’s innovative technology aims to improve outcomes in cardiac surgeries by providing tissue that grows with the patient.
A profile of Annoviant’s mission to develop regenerative tissue solutions for heart disease, emphasizing their TxGuard platform and clinical progress.
Details about NIH funding to support the development of a regenerative conduit for pediatric heart patients.
Received a $2.99 million SBIR Phase 2b grant from NIH to develop and commercialize a regenerative conduit for pediatric heart disease.
Awarded a $1.85 million NIH SBIR Phase II grant to further develop a tissue-engineered pulmonary valve conduit for children with congenital heart disease.